Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.
Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.
PF-07985045 (panKRAS NG) | Project advanced
selective pan KRAS inhibitor
PF-07921585 (PD1-IL12) | Project advanced
IL-12 partial agonist
PF-08052666 (MesoC2) | New project
mesothelin-targeted antibody-drug conjugate